Advocacy for Homeopathy Working Group
The Advocacy for Homeopathy Working Group (AHWG) first convened in 2017 for national and state homeopathic organizations to speak with a unified voice and advocate for continued access to and use of homeopathic products and services. This gathering was in response to a September 2016 FDA-issued warning that homeopathic teething tablets might not be safe. AWHG meets monthly.
Prior to issuing the teething tablet warning, the Food and Drug Administration (FDA) had a two-day listening session in April 2015 that was defined as an opportunity for experts and members of the public to help the FDA decide how it should regulate homeopathic products. In September 2015, the Federal Trade Commission (FTC) convened a workshop to examine how homeopathic drugs are marketed to consumers. The workshop was followed by issuance of a new “Enforcement Policy Statement on Marketing Claims for Over-the-Counter (OTC) Homeopathic Drugs.”
- Implement a unified media/communication plan with specific strategies for messaging and reaching defined audiences to support advocacy efforts.
- Use existing organizational communication to ensure correct and up-to-date information on emerging issues that affect homeopathy.
- Identify existing homeopathy materials and resources to support advocacy efforts.
- Develop materials that feature homeopathy as an effective and affordable healthcare solution for many major healthcare issues (e.g., chronic disease, autoimmune disease, infectious disease, antibiotic resistance, pain management, addiction, underserved populations, etc.).
- Create response templates for all homeopathy organizations to use and timely disseminate for specific advocacy efforts (e.g., FDA, FTC, etc.).